title: Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?
abstract: OBJECTIVE
  To assess the role of age in the results of bilateral deep brain stimulation in the subthalamic nucleus (DBS-STN), we carried out a study of two groups of patients regarding age at time of surgery.
  
  
  METHODS
  We compared, up to 2 years after surgery, the clinical effects, safety, and quality of life in parkinsonian patients younger than 65 years old (young patients) vs parkinsonian patients 65 years old or older (old patients).
  
  
  RESULTS
  The mean age was 57.4 +/- 4.9 years (n = 53) in young patients and 68.8 +/- 2.8 years (n = 34) in old patients. A dramatic improvement in motor complications was equally observed in both groups of patients. There was no significant difference between the groups regarding acute effects of DBS-STN on the motor score of the Unified Parkinson's Disease Rating Scale part III (UPDRS III). Time course evolution of UPDRS the motor score (p < 0.0001) and axial score (p = 0.0001) assessed postoperatively in "on" medication and "on" stimulation conditions appeared worse in old patients as compared to young patients. Improvement in the Schwab and England Scale score was better in young patients in "on" (p < 0.0003) and "off" state (p < 0.001). Quality of life assessed with the 39-item Parkinson's Disease Questionnaire showed an improvement in subscales evaluating mobility (p < 0.0001), activities of daily life (p < 0.0001), emotion and stigma (p = 0.0004), cognition (p < 0.0074), and communication (p = 0.0029) in young patients as compared to old patients. Side effects were similar in the two groups.
  
  
  CONCLUSIONS
  Although deep brain stimulation in the subthalamic nucleus reduces motor complications equally in both groups of patients, postoperative quality of life improved only in young patients.
authors: Univ Clermont 1, EA 3845, Service de Neurologie, Clermont-Ferrand CEDEX 1, France. pderost@chu-clermontferrand.fr
authors: P-P
authors: PP
authors: Derost
authors: L
authors: L
authors: Ouchchane
authors: D
authors: D
authors: Morand
authors: M
authors: M
authors: Ulla
authors: P-M
authors: PM
authors: Llorca
authors: M
authors: M
authors: Barget
authors: B
authors: B
authors: Debilly
authors: J-J
authors: JJ
authors: Lemaire
authors: F
authors: F
authors: Durif
mesh_terms: D000203:Activities of Daily Living; D000367:Age Factors; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000209:etiology; D002396:Catechols / Q000627:therapeutic use; D003071:Cognition; D003131:Combined Modality Therapy; D003142:Communication; D046690:Deep Brain Stimulation / Q000009:adverse effects; D004401:Dysarthria / Q000209:etiology; D004567:Electrodes, Implanted / Q000009:adverse effects; D004644:Emotions; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009068:Movement; D009483:Neuropsychological Tests; D009570:Nitriles / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D010479:Pergolide / Q000627:therapeutic use; D011287:Prejudice; D011788:Quality of Life; D012720:Severity of Illness Index; D020531:Subthalamic Nucleus / Q000293:injuries / Q000503:physiopathology*; D016896:Treatment Outcome; D015430:Weight Gain
chemical_list: D000978:Antiparkinson Agents; D002396:Catechols; D009570:Nitriles; D010479:Pergolide; D007980:Levodopa; C071192:entacapone